Before you sell to, join or invest in EnZeta Immunotherapies, Inc.
MentionFox check on EnZeta Immunotherapies, Inc.: only 2 sources on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/enzeta-immunotherapies-inc-form-d-25000001
Check EnZeta Immunotherapies, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about EnZeta Immunotherapies, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
EnZeta Immunotherapies, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-02-20.
EnZeta Immunotherapies, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on February 20, 2025. The filing reports $840K sold. Its industry group is Biotechnology. It names Paul Kelly (Executive Officer, Director), Sergio Traversa (Director) (SEC Form D/A, February 20, 2025).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like EnZeta Immunotherapies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns EnZeta Immunotherapies, Inc.
Free to see. No signup.
More on the people and the money behind EnZeta Immunotherapies, Inc., from the filings we hold.
Biotechnology raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when EnZeta Immunotherapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when EnZeta Immunotherapies, Inc. raises, hires or launches. No email unless you switch it on.
Watch EnZeta Immunotherapies, Inc. →Get the full cited report on EnZeta Immunotherapies, Inc.
What the filing shows about EnZeta Immunotherapies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on EnZeta Immunotherapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives EnZeta Immunotherapies, Inc.'s address as 122 Sevilla Ave # 919, Coral Gables, FL 33134.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for EnZeta Immunotherapies, Inc. →
Amended on 2026-03-06: the offering size changed from $1,000,000 to $2,370,000; the amount sold changed from $200,000 to $840,000; the number of investors changed from 3 to 10. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on EnZeta Immunotherapies, Inc. See pricing
EnZeta Immunotherapies, Inc. is a registered filer with the SEC (CIK 1994145) and has filed since 2023-09-26. 4 filings are on record, the latest on 2026-03-06.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
EnZeta Immunotherapies, Inc.'s Form D of 2025-02-20 names Paul Kelly and Sergio Traversa as its officers, directors or promoters.
Its new offerings report $215K sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
Paul Kelly is named as Executive Officer and Director on the Form D that EnZeta Immunotherapies, Inc. filed with the SEC on 20 February 2025, one of 2 people that filing names.
Sergio Traversa is named as Director on the Form D that EnZeta Immunotherapies, Inc. filed with the SEC on 20 February 2025, one of 2 people that filing names.
2 people named on the filing — 1 holding an executive role and 1 as a director only.
Named as of the 2025-02-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about EnZeta Immunotherapies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on EnZeta Immunotherapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on EnZeta Immunotherapies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist EnZeta Immunotherapies, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind EnZeta Immunotherapies, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for EnZeta Immunotherapies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Miami
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/enzeta-immunotherapies-inc-form-d-25000001